Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study

References

• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. New Eng J Med. 2010;363:1938–1948. doi:10.1056/NEJMra1001389
   PubMed Web of Science ®Google Scholar
• Kelly PN. The Cancer Immunotherapy Revolution. Science. 2018;359:1344–1345. doi:10.1126/science.359.6382.1344
   PubMed Web of Science ®Google Scholar
• van Rooijen JM, Stutvoet TS, Schröder CP, de Vries EGE. Immunotherapeutic options on the horizon in breast cancer treatment. Pharmacol Ther. 2015;156:90–101. doi:10.1016/j.pharmthera.2015.09.003
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361–370. doi:10.1158/2326-6066.CIR-13-0127
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–686. doi:10.1007/s10549-017-4537-5
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(74):74. doi:10.1001/jamaoncol.2018.4224
   PubMedGoogle Scholar
• Cortes J, Cescon DW, Rugo HS, et al. KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Am Soc Clin Oncol. 2020;38:1000. doi:10.1200/JCO.2020.38.15_suppl.1000
   Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Annal Oncol. 2019;30:397–404. doi:10.1093/annonc/mdy517
   PubMed Web of Science ®Google Scholar
• Sistigu A, Viaud S, Chaput N, et al. Immunomodulatory Effects of Cyclophosphamide and Implementations for Vaccine Design. Springer; 2011. doi:10.1007/s00281-011-0245-0
   Google Scholar
• Ghiringhelli F, Menard C, Puig PE, et al. Related papers Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK eVector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–648. doi:10.1007/s00262-006-0225-8
   PubMed Web of Science ®Google Scholar
• Ménétrier-Caux C, Ray-Coquard I, Blay J-Y, Caux C. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immuno Ther Cancer. 2019;7(85). doi:10.1186/s40425-019-0549-5
   Google Scholar
• Trédan O, Ray-Coquard I, Chvetzoff G, et al. Validation of prognostic scores for survival in cancer patients beyond first-line therapy. BMC Cancer. 2011;11. doi:10.1186/1471-2407-11-95
   Web of Science ®Google Scholar
• Manuel M, Tredan O, Bachelot T, et al. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology. 2012;1(432):432–440. doi:10.4161/onci.19545
   PubMedGoogle Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, Phase 3 clinical trial. Lancet. 2020;396:1817–1828. doi:10.1016/S0140-6736(20)32531-9
   PubMed Web of Science ®Google Scholar
• Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143:330–337. doi:10.5858/arpa.2018-0043-OA
   PubMed Web of Science ®Google Scholar
• Verronèse E, Delgado A, Valladeau-Guilemond J, et al. Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. Oncoimmunology. 2015;5. doi:10.1080/2162402X.2015.1100791
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128. doi:10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48–61. doi:10.1016/j.cell.2014.12.033
   PubMed Web of Science ®Google Scholar
• Cortés J, Guo Z, Karantza V, Aktan G. KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC). Annals of Oncology. Available from: https://www.annalsofoncology.org/article/S0923-7534(19)56089-6/fulltext. Accessed April 11, 2023.
   Google Scholar
• Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–5391. doi:10.1158/0008-5472.CAN-08-3845
   PubMed Web of Science ®Google Scholar
• Winer EP, Lipatov O, Im S-A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:499–511. doi:10.1016/S1470-2045(20)30754-3
   PubMed Web of Science ®Google Scholar
• Scurr M, Pembroke T, Bloom A, et al. Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin Cancer Res. 2017;23:6771–6780. doi:10.1158/1078-0432.CCR-17-0895
   PubMed Web of Science ®Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920–928. doi:10.1038/s41591-019-0432-4
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–571. doi:10.1038/nature13954
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Catherine Sautès-Fridman. 1922;577(25):549–555.
   Google Scholar
• Dieci MV, Miglietta F, Guarneri V. Immune infiltrates in breast cancer: recent updates and clinical implications. Cells. 2021;10:223. doi:10.3390/cells10020223
   PubMed Web of Science ®Google Scholar
• Liu J, Li Y, Li Q, et al. Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. Breast Cancer Res Treat. 2021;186:687–697. doi:10.1007/s10549-021-06128-4
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Pillai RN, Yang S, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114:4993–4998. doi:10.1073/pnas.1705327114
   PubMed Web of Science ®Google Scholar
• Huang A, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. J Nat Disasters. 2017;26:60. doi:10.1038/nature22079
   Google Scholar
• Kim KH, Cho J, Ku BM, et al. The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to Anti-PD-1 therapy in solid tumors. Clin Cancer Res. 2019;25:2144–2154. doi:10.1158/1078-0432.CCR-18-1449
   PubMed Web of Science ®Google Scholar